A revolutionary CAR T cell therapy for lymphoid tumours
January 16, 2025
 |
Read full article |
| Article Title: | A revolutionary CAR T cell therapy for lymphoid tumours |
| Authors: | Laib B., Laib A., Kherraf D. |
| Affiliation: | Faculty of Nature and Life Sciences, Department of Ecology and Environment, Batna University 2, Algeria Hematology and oncology department, Nancy Hospital, France |
| Abstract: | The development of new approaches to anti-tumour immunotherapies is booming. Advances in molecular biology and the development of various genetic manipulation tools make it possible to reprogram T lymphocytes to express a chimeric receptor including the variable part of an immunoglobulin capable of recognizing a tumor antigen associated with the expression of molecules inducing the activation of T lymphocytes. The genetically modified T cells, known as CAR (chimeric antigen receptor)-T cells, have achieved impressive clinical results in the treatment of relapsed or refractory B lymphoid haemopathies and are under development in solid tumors. T cells have powerful lytic functions and their specific targeting of tumour cells for destruction is a major challenge. These CARs, designed for the treatment of hematological malignancies, make it possible to envisage the construction of other CARs directed against solid tumors. |
| Keywords: | tumor, immunotherapy, CAR-T CELLS, Lymphoma. |
| *Correspondence: | Abir Laib, Hematology and oncology department, Nancy hospital, France, email: laib.abir@gmail.com |
About The Author
